<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>AJMC articles</title><description>AJMC articles</description><link>https://www.ajmc.com/news</link><category>AJMC articles</category><copyright>© 2026 MJH Life Sciences™ and AJMC. All rights reserved.</copyright><lastBuildDate>Sat, 10 Oct 2026 22:54:20 +0000</lastBuildDate><ttl>5</ttl><atom:link href="https://www.ajmc.com/rss.xml" rel="self" type="application/rss+xml"/><language>en-us</language><image><title>AJMC articles</title><width>144</width><height>47</height><link>https://www.ajmc.com/news</link><url>https://www.ajmc.com/logo.webp</url></image><item><title>&lt;![CDATA[Keynote Address Tackles AI’s Role in Health Care, Eye Care]]&gt;</title><link>https://www.ajmc.com/view/keynote-address-tackles-ai-s-role-in-health-care-eye-care</link><guid isPermaLink="true">https://www.ajmc.com/view/keynote-address-tackles-ai-s-role-in-health-care-eye-care</guid><description>&lt;![CDATA[The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.]]&gt;</description><pubDate>Sat, 10 Oct 2026 22:00:25 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Using AI to Advance Equity in Eye Care: Grayson W. Armstrong, MD, MPH]]&gt;</title><link>https://www.ajmc.com/view/using-ai-to-advance-equity-in-eye-care-grayson-w-armstrong-md-mph</link><guid isPermaLink="true">https://www.ajmc.com/view/using-ai-to-advance-equity-in-eye-care-grayson-w-armstrong-md-mph</guid><description>&lt;![CDATA[Cost, staffing, unbiased training data, and strong referral partnerships will decide whether AI eye screening reaches patients at highest risk of vision loss.]]&gt;</description><pubDate>Sat, 10 Oct 2026 21:52:44 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery]]&gt;</title><link>https://www.ajmc.com/view/glp-1s-have-protective-benefit-against-dme-glaucoma-surgery</link><guid isPermaLink="true">https://www.ajmc.com/view/glp-1s-have-protective-benefit-against-dme-glaucoma-surgery</guid><description>&lt;![CDATA[Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
]]&gt;</description><pubDate>Sat, 10 Oct 2026 14:30:57 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Medicaid Expansion Associated With Lower Colorectal Cancer Mortality]]&gt;</title><link>https://www.ajmc.com/view/medicaid-expansion-associated-with-lower-colorectal-cancer-mortality</link><guid isPermaLink="true">https://www.ajmc.com/view/medicaid-expansion-associated-with-lower-colorectal-cancer-mortality</guid><description>&lt;![CDATA[Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.]]&gt;</description><pubDate>Sat, 10 Oct 2026 14:30:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD]]&gt;</title><link>https://www.ajmc.com/view/pairing-vyd2311-with-mrna-covid-19-vaccines-michael-mina-md-phd</link><guid isPermaLink="true">https://www.ajmc.com/view/pairing-vyd2311-with-mrna-covid-19-vaccines-michael-mina-md-phd</guid><description>&lt;![CDATA[Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.]]&gt;</description><pubDate>Sat, 10 Oct 2026 14:10:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care]]&gt;</title><link>https://www.ajmc.com/view/nei-director-highlights-pediatric-advances-ai-s-promise-in-eye-care</link><guid isPermaLink="true">https://www.ajmc.com/view/nei-director-highlights-pediatric-advances-ai-s-promise-in-eye-care</guid><description>&lt;![CDATA[The director of the National Eye Institute discusses recent advances, AI, and evolving standards of care in ophthalmology.]]&gt;</description><pubDate>Sat, 10 Oct 2026 13:05:18 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts]]&gt;</title><link>https://www.ajmc.com/view/multi-hit-tp53-linked-to-shorter-survival-in-chronic-phase-mpn-cohorts</link><guid isPermaLink="true">https://www.ajmc.com/view/multi-hit-tp53-linked-to-shorter-survival-in-chronic-phase-mpn-cohorts</guid><description>&lt;![CDATA[TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.]]&gt;</description><pubDate>Fri, 09 Oct 2026 21:08:50 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Navigating GLP-1 Access &amp; Prior Authorizations: Amanda Velazquez, MD]]&gt;</title><link>https://www.ajmc.com/view/navigating-glp-1-access-prior-authorizations-amanda-velazquez-md</link><guid isPermaLink="true">https://www.ajmc.com/view/navigating-glp-1-access-prior-authorizations-amanda-velazquez-md</guid><description>&lt;![CDATA[Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.]]&gt;</description><pubDate>Fri, 09 Oct 2026 21:01:05 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Matching Respiratory Tests to Patients: Connie Savor, MD, MBA]]&gt;</title><link>https://www.ajmc.com/view/matching-respiratory-tests-to-patients-connie-savor-md-mba</link><guid isPermaLink="true">https://www.ajmc.com/view/matching-respiratory-tests-to-patients-connie-savor-md-mba</guid><description>&lt;![CDATA[Cepheid&apos;s Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.]]&gt;</description><pubDate>Fri, 09 Oct 2026 19:20:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Medicare Leads 10 Countries on Access to Care but Lags on Affordability]]&gt;</title><link>https://www.ajmc.com/view/medicare-leads-10-countries-on-access-to-care-but-lags-on-affordability</link><guid isPermaLink="true">https://www.ajmc.com/view/medicare-leads-10-countries-on-access-to-care-but-lags-on-affordability</guid><description>&lt;![CDATA[Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.]]&gt;</description><pubDate>Fri, 09 Oct 2026 17:17:08 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Specialty Pharmacists Flag Symptoms, Sustain Adherence in ATTR-CM]]&gt;</title><link>https://www.ajmc.com/view/specialty-pharmacists-flag-symptoms-sustain-adherence-in-attr-cm</link><guid isPermaLink="true">https://www.ajmc.com/view/specialty-pharmacists-flag-symptoms-sustain-adherence-in-attr-cm</guid><description>&lt;![CDATA[Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.]]&gt;</description><pubDate>Fri, 09 Oct 2026 16:55:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Diagnostic Delays Linked to Greater Disease Activity, Worse Quality of Life in Sjögren Disease]]&gt;</title><link>https://www.ajmc.com/view/diagnostic-delays-linked-to-greater-disease-activity-worse-quality-of-life-in-sj-gren-disease</link><guid isPermaLink="true">https://www.ajmc.com/view/diagnostic-delays-linked-to-greater-disease-activity-worse-quality-of-life-in-sj-gren-disease</guid><description>&lt;![CDATA[Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.]]&gt;</description><pubDate>Fri, 09 Oct 2026 16:48:16 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Kerry Rogers, MD, Weighs CAR T Against Bispecifics in CLL]]&gt;</title><link>https://www.ajmc.com/view/kerry-rogers-md-weighs-car-t-against-bispecifics-in-cll</link><guid isPermaLink="true">https://www.ajmc.com/view/kerry-rogers-md-weighs-car-t-against-bispecifics-in-cll</guid><description>&lt;![CDATA[Duration of benefit &quot;has to be part of the discussion,&quot; emphasizes Rogers of The James/The Ohio State Comprehensive Cancer Center.]]&gt;</description><pubDate>Fri, 09 Oct 2026 15:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[5 Things to Know About Eye Injury Prevention Month]]&gt;</title><link>https://www.ajmc.com/view/5-things-to-know-about-eye-injury-prevention-month</link><guid isPermaLink="true">https://www.ajmc.com/view/5-things-to-know-about-eye-injury-prevention-month</guid><description>&lt;![CDATA[An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home. ]]&gt;</description><pubDate>Fri, 09 Oct 2026 14:45:22 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL]]&gt;</title><link>https://www.ajmc.com/view/full-polargo-data-reveal-os-safety-for-pola-r-gemox-in-dlbcl</link><guid isPermaLink="true">https://www.ajmc.com/view/full-polargo-data-reveal-os-safety-for-pola-r-gemox-in-dlbcl</guid><description>&lt;![CDATA[Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.]]&gt;</description><pubDate>Fri, 09 Oct 2026 13:59:56 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia]]&gt;</title><link>https://www.ajmc.com/view/fda-approves-once-monthly-subcutaneous-olanzapine-for-schizophrenia</link><guid isPermaLink="true">https://www.ajmc.com/view/fda-approves-once-monthly-subcutaneous-olanzapine-for-schizophrenia</guid><description>&lt;![CDATA[Teva&apos;s Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.]]&gt;</description><pubDate>Fri, 09 Oct 2026 13:55:35 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Community Oncology Delivers Strong Outcomes: Nicolas Ferreyros]]&gt;</title><link>https://www.ajmc.com/view/community-oncology-delivers-strong-outcomes-nicolas-ferreyros</link><guid isPermaLink="true">https://www.ajmc.com/view/community-oncology-delivers-strong-outcomes-nicolas-ferreyros</guid><description>&lt;![CDATA[COA&apos;s Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.]]&gt;</description><pubDate>Fri, 09 Oct 2026 13:52:42 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[CLL Treatment Access Lags Behind Innovation Amid Testing, Step Therapy Gaps  ]]&gt;</title><link>https://www.ajmc.com/view/cll-treatment-access-lags-behind-innovation-amid-testing-step-therapy-gaps</link><guid isPermaLink="true">https://www.ajmc.com/view/cll-treatment-access-lags-behind-innovation-amid-testing-step-therapy-gaps</guid><description>&lt;![CDATA[Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.]]&gt;</description><pubDate>Thu, 08 Oct 2026 20:39:11 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Global Heart Failure Cases More Than Doubled to 56 Million Since 1990]]&gt;</title><link>https://www.ajmc.com/view/global-heart-failure-cases-more-than-doubled-to-56-million-since-1990</link><guid isPermaLink="true">https://www.ajmc.com/view/global-heart-failure-cases-more-than-doubled-to-56-million-since-1990</guid><description>&lt;![CDATA[Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.]]&gt;</description><pubDate>Thu, 08 Oct 2026 20:31:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer]]&gt;</title><link>https://www.ajmc.com/view/fda-approves-iv-subcutaneous-atezolizumab-for-dmmr-colon-cancer</link><guid isPermaLink="true">https://www.ajmc.com/view/fda-approves-iv-subcutaneous-atezolizumab-for-dmmr-colon-cancer</guid><description>&lt;![CDATA[The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.]]&gt;</description><pubDate>Thu, 08 Oct 2026 19:36:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Order Sets, Pharmacist Protocols Target Iron Deficiency Gaps in HF]]&gt;</title><link>https://www.ajmc.com/view/order-sets-pharmacist-protocols-target-iron-deficiency-gaps-in-hf</link><guid isPermaLink="true">https://www.ajmc.com/view/order-sets-pharmacist-protocols-target-iron-deficiency-gaps-in-hf</guid><description>&lt;![CDATA[Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.]]&gt;</description><pubDate>Thu, 08 Oct 2026 18:45:35 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD]]&gt;</title><link>https://www.ajmc.com/view/timing-covid-19-protection-with-vyd2311-michael-mina-md-phd</link><guid isPermaLink="true">https://www.ajmc.com/view/timing-covid-19-protection-with-vyd2311-michael-mina-md-phd</guid><description>&lt;![CDATA[Michael Mina, MD, PhD, explains Invivyd&apos;s accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.]]&gt;</description><pubDate>Thu, 08 Oct 2026 18:13:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Cost Top Barrier to CKD Drug Access]]&gt;</title><link>https://www.ajmc.com/view/cost-top-barrier-to-ckd-drug-access</link><guid isPermaLink="true">https://www.ajmc.com/view/cost-top-barrier-to-ckd-drug-access</guid><description>&lt;![CDATA[The study authors note there is an urgent need for &quot;innovative value-based and alternative payment models of care.&quot;]]&gt;</description><pubDate>Thu, 08 Oct 2026 17:11:47 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[AI, Eye Care Will Take Center Stage at AAO 2026]]&gt;</title><link>https://www.ajmc.com/view/ai-eye-care-will-take-center-stage-at-aao-2026</link><guid isPermaLink="true">https://www.ajmc.com/view/ai-eye-care-will-take-center-stage-at-aao-2026</guid><description>&lt;![CDATA[The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.]]&gt;</description><pubDate>Thu, 08 Oct 2026 17:05:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Heat Deaths Highest Among Military, Farm, Construction]]&gt;</title><link>https://www.ajmc.com/view/heat-deaths-highest-among-military-farm-construction</link><guid isPermaLink="true">https://www.ajmc.com/view/heat-deaths-highest-among-military-farm-construction</guid><description>&lt;![CDATA[A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.]]&gt;</description><pubDate>Thu, 08 Oct 2026 16:59:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[AJMC® in the Press, October 9, 2026]]&gt;</title><link>https://www.ajmc.com/view/ajmc-in-the-press-october-9-2026</link><guid isPermaLink="true">https://www.ajmc.com/view/ajmc-in-the-press-october-9-2026</guid><description>&lt;![CDATA[Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.]]&gt;</description><pubDate>Thu, 08 Oct 2026 16:18:15 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Early-Onset BRAF Patients Need Faster Treatment: Cathy Eng, MD, FACP, FASCO]]&gt;</title><link>https://www.ajmc.com/view/early-onset-braf-patients-need-faster-treatment-cathy-eng-md-facp-fasco</link><guid isPermaLink="true">https://www.ajmc.com/view/early-onset-braf-patients-need-faster-treatment-cathy-eng-md-facp-fasco</guid><description>&lt;![CDATA[Cathy Eng, MD, discusses a BREAKWATER post hoc analysis showing poorer survival in early-onset BRAF V600E colorectal cancer.]]&gt;</description><pubDate>Thu, 08 Oct 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Bumetanide Nasal Spray Targets Heart Failure Edema Before IV]]&gt;</title><link>https://www.ajmc.com/view/bumetanide-nasal-spray-targets-heart-failure-edema-before-iv</link><guid isPermaLink="true">https://www.ajmc.com/view/bumetanide-nasal-spray-targets-heart-failure-edema-before-iv</guid><description>&lt;![CDATA[Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.]]&gt;</description><pubDate>Thu, 08 Oct 2026 14:37:41 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[PhRMA Sues to Block CMS Most Favored Nation Model for Part B]]&gt;</title><link>https://www.ajmc.com/view/phrma-sues-to-block-cms-most-favored-nation-model-for-part-b</link><guid isPermaLink="true">https://www.ajmc.com/view/phrma-sues-to-block-cms-most-favored-nation-model-for-part-b</guid><description>&lt;![CDATA[The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.]]&gt;</description><pubDate>Thu, 08 Oct 2026 14:36:03 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item><item><title>&lt;![CDATA[Keeping Patients on Multiple Myeloma Bispecifics: Beth Faiman, PhD]]&gt;</title><link>https://www.ajmc.com/view/keeping-patients-on-multiple-myeloma-bispecifics-beth-faiman-phd</link><guid isPermaLink="true">https://www.ajmc.com/view/keeping-patients-on-multiple-myeloma-bispecifics-beth-faiman-phd</guid><description>&lt;![CDATA[Cleveland Clinic&apos;s Beth Faiman, PhD, MSN, discusses AP-led clinics, managing talquetamab taste changes, and infection prophylaxis with bispecifics.]]&gt;</description><pubDate>Thu, 08 Oct 2026 14:31:00 GMT</pubDate><media:credit role="publishing company">AJMC</media:credit><category>us</category><source url="https://www.ajmc.com/rss.xml">AJMC Articles</source></item></channel></rss>